Issued 2026-09-16 at $10.80 · now $10.80 (2026-09-16, +0.0% since)
Based on its own history, a month from the 2026-09-16 close, HLXC has typically landed between $10.64 and $11.40 — a range of −1.5% to +5.5% from the issuance price $10.80.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
143 overlapping 1 month windows · 2026-01-22 – 2026-08-17 · basis climatology · forecast (batch).
The cone is anchored at the 2026-09-16 issuance close ($10.80) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where HLXC has typically landed a month from the 2026-09-16 close of $10.8 — the range is history, not a prediction.
- now $10.8 (+0.0%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $10.86 (+0.6%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $10.75–$10.98
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $10.64–$11.4
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2026-08-14 | −1.8% | −3.3% | +3.6% |
| 2026-06-15 | −1.4% | −1.4% | +2.8% |
| 2026-04-08 | −1.4% | −1.5% | +0.0% |
| 3 best | |||
| 2026-07-27 | +8.4% | −0.1% | +8.4% |
| 2026-07-16 | +7.8% | +0.0% | +7.8% |
| 2026-05-29 | +4.2% | +0.0% | +4.2% |
143 overlapping windows · 2026-01-22 – 2026-09-16 · not cherry-picked
Reported insider & political trades
Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.
| Date | Person | Role | Action | Shares @ price | Value | Ownership Δ | vs S&P 1m | vs S&P 6m | Owned after | Filing |
|---|
The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.
4 award / exercise / gift records — not counted as purchases
Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.
| Date | Person | Role | Action | Shares | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-01-26 | Chen Bihua | director | Award / grant | 497,500 | 497,500 | Form 4 |
| 2026-01-22 | Chen Bihua | director | Other acquisition | 718,750 | 4,252,500 | Form 4 |
| 2026-01-22 | Chen Bihua | director | Other acquisition | 718,750 | 4,252,500 | Form 4 |
| 2026-01-22 | Chen Bihua | director | Other acquisition | 718,750 | 4,252,500 | Form 4 |
Source: SEC Form 4 filings. Each row links to its original filing.
Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.